title: [Anticoagulant therapy in connection with cardioversion in patients with atrial fibrillation].
abstract: We present data on possibility of anticoagulant therapy in conjunction with electrical cardioversion in patients with atrial fibrillation using novel anticoagulant - dabigatran - and a case of successful lysis of thrombus in the left ventricular cavity at the background of its administration.
authors.forename: N V
authors.initials: NV
authors.lastname: Furman
authors.forename: L E
authors.initials: LE
authors.lastname: Kuvshinova
authors.forename: Ia P
authors.initials: IaP
authors.lastname: Dovgalevskiĭ
mesh_terms: D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001281:Atrial Fibrillation / Q000503:physiopathology / Q000628:therapy; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001682:Biological Availability; D001777:Blood Coagulation / Q000187:drug effects*; D000069604:Dabigatran; D016903:Drug Monitoring / Q000379:methods; D017548:Echocardiography, Transesophageal; D004554:Electric Countershock / Q000379:methods*; D005260:Female; D006325:Heart Atria / Q000000981:diagnostic imaging / Q000503:physiopathology; D006339:Heart Rate; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D060735:Pharmacovigilance; D020379:Risk Adjustment; D013927:Thrombosis / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000517:prevention & control; D016896:Treatment Outcome; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
chemical_list: D000991:Antithrombins; D001562:Benzimidazoles; D015091:beta-Alanine; D000069604:Dabigatran